HRP20190943T1 - Derivat 2-acilaminotiazola za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava - Google Patents
Derivat 2-acilaminotiazola za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava Download PDFInfo
- Publication number
- HRP20190943T1 HRP20190943T1 HRP20190943TT HRP20190943T HRP20190943T1 HR P20190943 T1 HRP20190943 T1 HR P20190943T1 HR P20190943T T HRP20190943T T HR P20190943TT HR P20190943 T HRP20190943 T HR P20190943T HR P20190943 T1 HRP20190943 T1 HR P20190943T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- compound
- substituted
- methyl
- Prior art date
Links
- 208000026533 urinary bladder disease Diseases 0.000 title claims 3
- 208000014001 urinary system disease Diseases 0.000 title claims 3
- 230000002265 prevention Effects 0.000 title claims 2
- 208000012931 Urologic disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 208000004168 Underactive Urinary Bladder Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- -1 -O-(C1-6 alkyl) Chemical group 0.000 claims 2
- VDNVCXNRNOMGIC-QGZVFWFLSA-N 3-[4-[5-[[4-[3-fluoro-5-(trifluoromethyl)phenyl]-5-[[(2R)-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]carbamoyl]pyrazin-2-yl]piperazin-1-yl]propanoic acid Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1CCN(CC1)CCC(=O)O VDNVCXNRNOMGIC-QGZVFWFLSA-N 0.000 claims 2
- HVKBNFPYZRQFGJ-QGZVFWFLSA-N C(C)N(CC)CC1=C(N=C(S1)NC(=O)C=1N=CC(=NC=1)N1C[C@H](N(CC1)CCC(=O)O)C)C1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C(C)N(CC)CC1=C(N=C(S1)NC(=O)C=1N=CC(=NC=1)N1C[C@H](N(CC1)CCC(=O)O)C)C1=CC(=CC(=C1)C(F)(F)F)F HVKBNFPYZRQFGJ-QGZVFWFLSA-N 0.000 claims 2
- OHZGFJZSNYLASQ-IAGOWNOFSA-N C[C@@H]1CN(CCN1C1=NC=C(N=C1)C(NC=1SC(=C(N=1)C=1SC=C(C=1)C(F)(F)F)CN1[C@@H](CCC1)C)=O)CCC(=O)O Chemical compound C[C@@H]1CN(CCN1C1=NC=C(N=C1)C(NC=1SC(=C(N=1)C=1SC=C(C=1)C(F)(F)F)CN1[C@@H](CCC1)C)=O)CCC(=O)O OHZGFJZSNYLASQ-IAGOWNOFSA-N 0.000 claims 2
- JNGXHDZVMVSOCP-QZTJIDSGSA-N C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC(=O)C=1N=CC(=NC=1)N1CCN(CC1)CCC(=O)O)C1=CC(=CC(=C1)C(F)(F)F)F Chemical compound C[C@H]1N([C@@H](CC1)C)CC1=C(N=C(S1)NC(=O)C=1N=CC(=NC=1)N1CCN(CC1)CCC(=O)O)C1=CC(=CC(=C1)C(F)(F)F)F JNGXHDZVMVSOCP-QZTJIDSGSA-N 0.000 claims 2
- QEVOTPLHYBIHKJ-SJORKVTESA-N ClC=1C=C(SC=1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1C[C@@H](N(CC1)CCC(=O)O)C Chemical compound ClC=1C=C(SC=1)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1C[C@@H](N(CC1)CCC(=O)O)C QEVOTPLHYBIHKJ-SJORKVTESA-N 0.000 claims 2
- NTYONJBNAXAEDY-IEBWSBKVSA-N ClC=1C=C(SC=1)C=1N=C(SC=1CN1[C@@H](CCC1)CC)NC(=O)C=1N=CC(=NC=1)N1C[C@H](N(CC1)CCC(=O)O)C Chemical compound ClC=1C=C(SC=1)C=1N=C(SC=1CN1[C@@H](CCC1)CC)NC(=O)C=1N=CC(=NC=1)N1C[C@H](N(CC1)CCC(=O)O)C NTYONJBNAXAEDY-IEBWSBKVSA-N 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Chemical group 0.000 claims 2
- MLYGKKZCMJXTAX-IAGOWNOFSA-N FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1[C@@H](CN(CC1)CC(=O)O)C Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1[C@@H](CN(CC1)CC(=O)O)C MLYGKKZCMJXTAX-IAGOWNOFSA-N 0.000 claims 2
- SJVQKALOOKKDRY-QZTJIDSGSA-N FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1[C@@H](CN(CC1)CCC(=O)O)C Chemical compound FC=1C=C(C=C(C=1)C(F)(F)F)C=1N=C(SC=1CN1[C@@H](CCC1)C)NC(=O)C=1N=CC(=NC=1)N1[C@@H](CN(CC1)CCC(=O)O)C SJVQKALOOKKDRY-QZTJIDSGSA-N 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Chemical group 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229910052731 fluorine Chemical group 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
Claims (17)
1. Spoj formule (I) ili njegova sol:
(pri čemu
R1 je -N(-R11)(-R12) ili ciklični amino koji može biti supstituiran s 1 do 5 supstituenata odabranih od skupine koja se sastoji od Skupine G i okso,
R11 je C1-6 alkil,
R12 je C1-6 alkil koji može biti supstituiran s 1 do 5 supstituenata odabranih od supstituenata (b) do (o) Skupine G ili C3-8 cikloalkil koji može biti supstituiran s 1 do 5 supstituenata odabranih od Skupine G,
R2 je aril, monociklični aromatični hetero prsten ili biciklični aromatični hetero prsten, koji svaki mogu biti supstituirani s 1 do 5 supstituenata odabranih od Skupine G,
R3-i su isti ili drugačiji jedni od drugih, i svaki je C1-6 alkil,
W je C1-6 alkilen i
n je cijeli broj od 0 do 4), pri čemu je Skupina G skupina koja se sastoji od:
(a) C1-6 alkila koji može biti supstituiran s barem jednom skupinom odabranom od skupine koja se sastoji od -OH, -O-(C1-6 alkila), -CN, -SO2-(C1-6 alkila) i halogena,
(b) -OH,
(c) -O-(C1-6 alkila koji može biti supstituiran s barem jednom skupinom odabranom od skupine koja se sastoji od -OH, -O-(C1-6 alkila), -CN, -SO2-(C1-6 alkila) i halogena),
(d) C3-8 cikloalkila,
(e) -O-(C3-8 cikloalkila),
(f) halogena,
(g) -CN,
(h) -SO2-(C1-6 alkila),
(i) -CO2-(C1-6 alkila) i -COOH,
(j) -CO-N(C1-6 alkila)2, -CO-NH(C1-6 alkila) i -CONH2,
(k) -CO-(C1-6 alkila),
(l) -SO2-N(C1-6 alkila)2, -SO2-NH(C1-6 alkila) i -SO2NH2,
(m) -N(C1-6 alkila)2, -NH(C1-6 alkila) i -NH2,
(n) zasićenog hetero prstena i
(o) -O-zasićenog hetero prstena.
2. Spoj ili njegova sol prema zahtjevu 1, pri čemu
R1 je
i. ciklični amino koji može biti supstituiran s 1 do 5 supstituenata odabranih od skupine koja se sastoji od Skupine G i okso ili
ii. -N(-R11)(-R12),
R11 je C1-6 alkil i
R12 je C1-6 alkil koji može biti supstituiran s 1 do 3 supstituenata odabranih od supstituenata opisanih u (b) do (g), i (n) Skupine G,
R2 je
i. fenil koji može biti supstituiran s 1 do 5 supstituenata odabranih od Skupine G,
ii. tienil koji može biti supstituiran s 1 do 3 supstituenata odabranih od Skupine G,
iii. piridil koji može biti supstituiran s 1 do 3 supstituenata odabranih od Skupine G ili
iv. benzotienil koji može biti supstituiran s 1 do 5 supstituenata odabranih od Skupine G.
3. Spoj ili njegova sol prema zahtjevu 2, pri čemu
R1 je
i. pirolidin-1-il ili piperidin-1-il, u kojem su pirolidin-1-il i piperidin-1-il svaki supstituirani s 1 do 2 supstituenta odabranih od skupine koja se sastoji od C1-6 alkila i halogen-C1-6 alkila ili
ii. -N(-R11)(-R12),
R11 je C1-6 alkil i
R12 je C1-6 alkil koji može biti supstituiran s jednom skupinom odabranom od skupine koja se sastoji od C3-8 cikloalkila i -O-(C1-6 alkila),
R2 je
i. fenil koji može biti supstituiran s 1 do 3 skupine odabrane od skupine koja se sastoji od C1-6 alkila, halogen-C1-6 alkila, -O-(C1-6 alkila), -O-(halogen-C1-6 alkila), halogena, C3-8 cikloalkila i -CN,
ii. tienil koji može biti supstituiran s 1 do 3 skupine odabrane od skupine koja se sastoji od C1-6 alkila, halogen-C1-6 alkila, -O-(C1-6 alkila), C3-8 cikloalkila i halogena,
iii. piridil koji može biti supstituiran s 1 do 3 skupine odabrane od skupine koja se sastoji od C1-6 alkila, halogen-C1-6 alkila, -O-(C1-6 alkila), C3-8 cikloalkila i halogena ili
iv. benzotienil,
W je C1-3 alkilen i
n je 0 ili 1.
4. Spoj ili njegova sol prema zahtjevu 3, pri čemu
R2 je
(a) fenil di-supstituiran s trifluorometilom i fluorom,
(b) tienil mono-supstituiran s triflurometilom ili klorom ili
(c) piridil di-supstituiran s trifluorometilom i metoksi i
W je metilen ili etilen.
5. Spoj ili njegova sol prema zahtjevu 3, pri čemu
R1 je pirolidin-1-il ili piperidin-1-il, u kojem su pirolidin-1-il i piperidin-1-il svaki supstituirani s 1 do 2 supstituenta odabranih od skupine koja se sastoji od C1-6 alkila i halogeno-C1-6 alkila i
R2 je
i. tienil koji može bit supstituiran s 1 ili 2 supstituenta odabranih od skupine koja se sastoji od halogeno-C1-6 alkila i halogena ili
ii. fenil koji može bit supstituiran s 1 ili 2 supstituenta odabranih od skupine koja se sastoji od halogeno-C1-6 alkila i halogena i
W je metilen ili etilen.
6. Spoj ili njegova sol prema zahtjevu 1, pri čemu spoj je spoj odabran od skupine koja se sastoji od:
3-[(2S)-4-(5-{[4-(4-klorotiofen-2-il)-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il]karbamoil}pirazin-2-il)-2-metilpiperazin-1-il]propanska kiselina,
3-[(3R)-4-{5-[(4-[3-fluoro-5-(trifluorometil)fenil]-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il)karbamoil]pirazin-2-il}-3-metilpiperazin-1-il]propanska kiselina,
[(3R)-4-{5-[(4-[3-fluoro-5-(trifluorometil)fenil]-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il)karbamoil]pirazin-2-il}-3-metilpiperazin-1-il]octena kiselina,
3-(4-{5-[(4-[3-fluoro-5-(trifluorometil)fenil]-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il)karbamoil]pirazin-2-il}piperazin-1-il)propanska kiselina,
3-[(2R)-4-(5-{[4-(4-klorotiofen-2-il)-5-{[(2R)-2-etilpirolidin-1-il]metil}-1,3-tiazol-2-il]karbamoil}pirazin-2-il)-2-metilpiperazin-1-il]propanska kiselina,
3-[(3R)-3-metil-4-{5-[(5-{[(2R)-2-metilpirolidin-1-il]metil}-4-[4-(trifluorometil)tiofen-2-il]-1,3-tiazol-2-il)karbamoil]pirazin-2-il}piperazin-1-il]propanska kiselina,
3-(4-{5-[(5-{[(2R,5R)-2,5-dimetilpirolidin-1-il]metil}-4-[3-fluoro-5-(trifluorometil)fenil]-1,3-tiazol-2-il)karbamoil]pirazin-2-il}piperazin-1-il)propanska kiselina i
3-{(2R)-4-[5-({5-[(dietilamino)metil]-4-[3-fluoro-5-(trifluorometil)fenil]-1,3-tiazol-2-il}karbamoil)pirazin-2-il]-2-metilpiperazin-1-il}propanska kiselina.
7. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-[(2S)-4-(5-{[4-(4-klorotiofen-2-il)-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il]karbamoil}pirazin-2-il)-2-metilpiperazin-1-il]propanska kiselina.
8. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-[(3R)-4-{5-[(4-[3-fluoro-5-(trifluorometil)fenil]-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il)karbamoil]pirazin-2-il}-3-metilpiperazin-1-il]propanska kiselina.
9. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
[(3R)-4-{5-[(4-[3-fluoro-5-(trifluorometil)fenil]-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il)karbamoil]pirazin-2-il}-3-metilpiperazin-1-il]octena kiselina.
10. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-(4-{5-[(4-[3-fluoro-5-(trifluorometil)fenil]-5-{[(2R)-2-metilpirolidin-1-il]metil}-1,3-tiazol-2-il)karbamoil]pirazin-2-il}piperazin-1-il)propanska kiselina.
11. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-[(2R)-4-(5-{[4-(4-klorotiofen-2-il)-5-{[(2R)-2-etilpirolidin-1-il]metil}-1,3-tiazol-2-il]karbamoil}pirazin-2-il)-2-metilpiperazin-1-il]propanska kiselina.
12. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-[(3R)-3-metil-4-{5-[(5-{[(2R)-2-metilpirolidin-1-il]metil}-4-[4-(trifluorometil)tiofen-2-il]-1,3-tiazol-2-il)karbamoil]pirazin-2-il}piperazin-1-il]propanska kiselina.
13. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-(4-{5-[(5-{[(2R,5R)-2,5-dimetilpirolidin-1-il]metil}-4-[3-fluoro-5-(trifluorometil)fenil]-1,3-tiazol-2-il)karbamoil]pirazin-2-il}piperazin-1-il)propanska kiselina.
14. Spoj ili njegova sol prema zahtjevu 6, pri čemu je spoj
3-{(2R)-4-[5-({5-[(dietilamino)metil]-4-[3-fluoro-5-(trifluorometil)fenil]-1,3-tiazol-2-il}karbamoil)pirazin-2-il]-2-metilpiperazin-1-il}propanska kiselina.
15. Farmaceutski sastav koji sadrži spoj ili njegovu sol prema zahtjevu 6 i farmaceutski prihvatljivu pomoćnu tvar.
16. Spoj ili njegova sol prema zahtjevu 6 za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava povezanih s kontrakcijama mjehura kroz muskarinski M3 receptor.
17. Spoj ili njegova sol prema zahtjevu 6 za uporabu prema zahtjevu 16, pri čemu je bolest mjehura/mokraćnog sustava povezana s disfunkcijom mokrenja ili disfunkcijom skladištenja urina kod mjehura smanjene aktivnosti, hipotoničnim mjehurom, akontraktilnim mjehurom, smanjenom aktivnosti detruzora ili neurogenskim mjehurom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014118046 | 2014-06-06 | ||
| EP15803484.3A EP3153511B1 (en) | 2014-06-06 | 2015-06-05 | 2-acylaminothiazole derivative for use in the prevention or treatment of bladder/urinary tract diseases |
| PCT/JP2015/066321 WO2015186821A1 (ja) | 2014-06-06 | 2015-06-05 | ２－アシルアミノチアゾール誘導体またはその塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190943T1 true HRP20190943T1 (hr) | 2019-09-20 |
Family
ID=54766887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190943TT HRP20190943T1 (hr) | 2014-06-06 | 2019-05-22 | Derivat 2-acilaminotiazola za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9951060B2 (hr) |
| EP (1) | EP3153511B1 (hr) |
| JP (1) | JP6319436B2 (hr) |
| KR (1) | KR102482844B1 (hr) |
| CN (2) | CN110845490B (hr) |
| AR (1) | AR100748A1 (hr) |
| AU (1) | AU2015269449B2 (hr) |
| BR (1) | BR112016028270B1 (hr) |
| CA (1) | CA2950564C (hr) |
| CO (1) | CO2017000044A2 (hr) |
| CY (1) | CY1122290T1 (hr) |
| DK (1) | DK3153511T3 (hr) |
| EA (1) | EA031866B1 (hr) |
| ES (1) | ES2732066T3 (hr) |
| HR (1) | HRP20190943T1 (hr) |
| HU (1) | HUE043496T2 (hr) |
| IL (1) | IL249356B (hr) |
| LT (1) | LT3153511T (hr) |
| MA (1) | MA39950B1 (hr) |
| ME (1) | ME03438B (hr) |
| MX (1) | MX370140B (hr) |
| MY (1) | MY197712A (hr) |
| NZ (1) | NZ727142A (hr) |
| PH (1) | PH12016502405A1 (hr) |
| PL (1) | PL3153511T3 (hr) |
| PT (1) | PT3153511T (hr) |
| RS (1) | RS58809B1 (hr) |
| SA (1) | SA516380427B1 (hr) |
| SG (2) | SG10202000463YA (hr) |
| SI (1) | SI3153511T1 (hr) |
| TR (1) | TR201908676T4 (hr) |
| TW (2) | TWI689507B (hr) |
| UA (1) | UA122208C2 (hr) |
| WO (1) | WO2015186821A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101563915B (zh) | 2006-12-20 | 2012-09-19 | Gvbb控股股份有限公司 | 嵌入音频路由切换器 |
| CA2959290A1 (en) | 2014-08-26 | 2016-03-03 | Astellas Pharma Inc. | 2-aminothiazole derivative or salt thereof |
| PT3555048T (pt) | 2016-12-19 | 2021-09-29 | Novartis Ag | Novos derivados de ácidos picolínicos e uso dos mesmos como intermediários |
| WO2019189766A1 (ja) * | 2018-03-30 | 2019-10-03 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| CN111718293A (zh) * | 2019-03-18 | 2020-09-29 | 持田制药株式会社 | 双芳基酰胺衍生物的制造方法 |
| EP3967311A1 (en) | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73543C2 (uk) * | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| JP2001278872A (ja) * | 2000-03-27 | 2001-10-10 | Banyu Pharmaceut Co Ltd | 新規アミノチアゾール誘導体 |
| EP1289965B1 (en) * | 2000-05-25 | 2005-10-26 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| JPWO2003037862A1 (ja) * | 2001-10-30 | 2005-02-17 | 日本新薬株式会社 | アミド誘導体及び医薬 |
| CA2472711C (en) * | 2002-01-18 | 2012-03-20 | Yamanouchi Pharmaceutical Co., Ltd. | 2-acylaminothiazole derivative or salt thereof |
| TWI242478B (en) | 2002-08-01 | 2005-11-01 | Masami Nakamoto | Metal nanoparticle and process for producing the same |
| TW200410951A (en) * | 2002-08-06 | 2004-07-01 | Glaxo Group Ltd | M3 muscarinic acetylcholine receptor antagonists |
| CN1835948B (zh) * | 2003-07-17 | 2010-05-26 | 安斯泰来制药有限公司 | 2-酰基氨基噻唑衍生物或其盐 |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| JP4665769B2 (ja) | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| RU2461551C2 (ru) * | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль |
| AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
| TWI647227B (zh) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
-
2015
- 2015-06-05 PL PL15803484T patent/PL3153511T3/pl unknown
- 2015-06-05 US US15/316,645 patent/US9951060B2/en not_active Ceased
- 2015-06-05 MX MX2016016134A patent/MX370140B/es active IP Right Grant
- 2015-06-05 EP EP15803484.3A patent/EP3153511B1/en active Active
- 2015-06-05 EA EA201692469A patent/EA031866B1/ru not_active IP Right Cessation
- 2015-06-05 RS RS20190710A patent/RS58809B1/sr unknown
- 2015-06-05 ES ES15803484T patent/ES2732066T3/es active Active
- 2015-06-05 DK DK15803484.3T patent/DK3153511T3/da active
- 2015-06-05 AU AU2015269449A patent/AU2015269449B2/en active Active
- 2015-06-05 HU HUE15803484A patent/HUE043496T2/hu unknown
- 2015-06-05 NZ NZ727142A patent/NZ727142A/en unknown
- 2015-06-05 ME MEP-2019-163A patent/ME03438B/me unknown
- 2015-06-05 WO PCT/JP2015/066321 patent/WO2015186821A1/ja active Application Filing
- 2015-06-05 MY MYPI2016704529A patent/MY197712A/en unknown
- 2015-06-05 KR KR1020177000217A patent/KR102482844B1/ko active IP Right Grant
- 2015-06-05 CN CN201911226515.2A patent/CN110845490B/zh active Active
- 2015-06-05 TW TW104118315A patent/TWI689507B/zh active
- 2015-06-05 US US16/856,738 patent/USRE49111E1/en active Active
- 2015-06-05 SG SG10202000463YA patent/SG10202000463YA/en unknown
- 2015-06-05 JP JP2016525246A patent/JP6319436B2/ja active Active
- 2015-06-05 TR TR2019/08676T patent/TR201908676T4/tr unknown
- 2015-06-05 TW TW109106548A patent/TWI745877B/zh active
- 2015-06-05 UA UAA201700205A patent/UA122208C2/uk unknown
- 2015-06-05 SI SI201530787T patent/SI3153511T1/sl unknown
- 2015-06-05 CN CN201580030154.8A patent/CN106414438B/zh active Active
- 2015-06-05 PT PT15803484T patent/PT3153511T/pt unknown
- 2015-06-05 MA MA39950A patent/MA39950B1/fr unknown
- 2015-06-05 CA CA2950564A patent/CA2950564C/en active Active
- 2015-06-05 BR BR112016028270-1A patent/BR112016028270B1/pt active IP Right Grant
- 2015-06-05 LT LTEP15803484.3T patent/LT3153511T/lt unknown
- 2015-06-05 AR ARP150101792A patent/AR100748A1/es active IP Right Grant
- 2015-06-05 SG SG11201610201UA patent/SG11201610201UA/en unknown
-
2016
- 2016-12-02 PH PH12016502405A patent/PH12016502405A1/en unknown
- 2016-12-04 IL IL24935616A patent/IL249356B/en active IP Right Grant
- 2016-12-05 SA SA516380427A patent/SA516380427B1/ar unknown
-
2017
- 2017-01-04 CO CONC2017/0000044A patent/CO2017000044A2/es unknown
-
2019
- 2019-05-22 HR HRP20190943TT patent/HRP20190943T1/hr unknown
- 2019-06-19 CY CY20191100631T patent/CY1122290T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190943T1 (hr) | Derivat 2-acilaminotiazola za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava | |
| RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| JP2016517878A5 (hr) | ||
| HRP20170357T1 (hr) | Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti | |
| HRP20220314T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori | |
| JP2013517278A5 (hr) | ||
| JP2014511869A5 (hr) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| HRP20140588T1 (hr) | Spojevi kondenziranog prstena i njihova uporaba | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| HRP20230789T1 (hr) | Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6 | |
| JP2007523905A5 (hr) | ||
| JP2017530185A5 (hr) | ||
| HRP20161797T1 (hr) | Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| JP2020516671A5 (hr) | ||
| JP2010513444A5 (hr) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2010540462A5 (hr) | ||
| JP2006500369A5 (hr) | ||
| HRP20120748T1 (hr) | Heterocikliäśki spoj i farmaceutski sastavi koji ga sadrže | |
| RU2010129078A (ru) | Производные циклопропиламина | |
| JP2015509510A5 (hr) |